Breaking Down Pneumococcal Conjugate vs Polysaccharide Vaccines

EP: 1.Clinical Presentation of Pneumococcal Disease in Children and Adults

EP: 2.Vulnerable Patients and the Burden of Pneumococcal Disease

Now Viewing

EP: 3.Breaking Down Pneumococcal Conjugate vs Polysaccharide Vaccines

EP: 4.Navigating CDC Recommendations for Pneumococcal Vaccines and Contraindications

Video content above is prompted by the following:

Five FDA-approved pneumococcal vaccines are currently available, including 4 conjugate vaccines (PCV13, PCV15, PCV20, PCV21) and 1 polysaccharide vaccine (PPSV23). Conjugate vaccines provide T-cell–dependent immune responses with superior immunologic memory, making them effective in pediatric populations and preferred for most adult vaccinations. PPSV23, developed in the 1980s, produces T-cell–independent responses with limited memory and requires revaccination in immunocompromised patients every 5 years.

PCV20 and PCV21 represent the newest generation of pneumococcal vaccines, with distinct advantages and coverage patterns. PCV20 covers 20 serotypes and was the first conjugate vaccine approved for adult use without requiring follow-up PPSV23 vaccination. PCV21 offers broader serotype coverage with approximately 85% coverage of invasive disease in adults 65 years and older compared with 54% coverage by PCV20, representing a 30% improvement in theoretical protection against invasive pneumococcal disease.

Geographic considerations influence vaccine selection, as PCV20 provides coverage for serotype 4, which is not included in PCV21 but remains prevalent in certain populations and regions, including Alaska, New Mexico, and Oregon. Patients at higher risk for serotype 4 disease include those younger than 65 years with alcohol use disorder, lung disease, smoking history, homelessness, or injection drug use. Health care providers must consider these epidemiologic factors when selecting between PCV20 and PCV21 to optimize protection for individual patients and communities.